Shots:VantAI and Blueprint Medicines have expanded their 2022 collaboration, adding new drug target programs to develop therapies for critical medical needsAs per the expansion, VantAI will receive up to $1.67B in total including ~$270M R&D and regulatory milestones, and $1.4B commercial milestones across four joint target programs, along with tiered mid-single-digit sales based…